ACE1831 is a type of treatment being studied for certain blood cancers. This treatment uses special cells called gamma delta T (gdT) cells that are taken from healthy people and given to patients. The study is called ACE1831-001 and is the first time this treatment is being tested in humans. The main goals of the study are to check if the treatment is safe, how it works in the body, and if it helps treat the cancer. To be part of this study, patients need to have a type of cancer called Non-Hodgkin lymphoma that hasn't improved with at least two other treatments. Certain health conditions and previous treatments might prevent participation.

• The study involves multiple visits for treatment and check-ups.
• Participants will not receive financial compensation.
• There are risks, including potential side effects from the treatment.